Our Mission – to become the leading platform company in the industry.
Following a buy and build strategy, SynBiotic supports & consolidates the
strongest players in the cannabinoids industry under one roof.
Our R&D portfolio will create new products, formulations and IP and conduct studies to:
We execute minority share investments in these companies, in order to get preferential access to the technology.
Our production & biotech companies convert the innovation generated by R&D into market-ready products.
We target >50% ownership of our companies.
With our medical and DTC portfolio we are acquiring and building profitable brands within our verticals to generate revenue.
We target >50% ownership of our companies.
Following a buy and build strategy, SynBiotic supports & consolidates the
strongest players in the cannabinoids industry under one roof.
Serial entrepreneur with over 10 years experience in scaling profitable companies.
In-depth industry know-how from seed to shelf, genetics, extraction methods & analytics such as product development. He is active in the cannabinoid business since 2015
As a serial entrepreneur his strength lies in strategy, ops and in coaching senior leadership, with particular expertise in post-merger-integration and capital market fitness. Sebastian has a master’s degree in business administration with a focus on IT supported marketing and human resources.
Dr. Marlon Braumann is a Serial Entrepreneur and one of the founding partners of the European VC fund Elevat3 Capital – an investment fund mainly focused on biotech, medtech, and fintech investments. Apart from that, Mr. Braumann is the founder of the global wildlife trust AMES Foundation.
Mr. Hanke has extensive transaction experience (private equity, venture capital, growth capital & PIPE transactions) and has, in addition to his work as an investor, also carried out various operational interim mandates within the scope of portfolio management.
Following his post-doctoral research, Le Roy became Quality Assurance Officer for Ulster’s Biomedical Sciences Research Institute (BMSRI). Le Roy holds a BSc (Hons) in Biochemistry from Queen’s University, Belfast and a PhD in Nutritional Biochemistry at Ulster University (2002). Le Roy joined the GreenLight Team in June 2018 and is now CEO.
As a scientist and a pharma expert, Dr. James Linden has built a world-class research network and the unique ability to aim R&D efforts at the most promising commercial opportunities. James holds a PhD in Biochemistry in the Department of Ophthalmology, Queens University Belfast.
Rainer Seiler has many years of leadership experience, including as Managing Director (Zur Rose Gruppe), as General Sales Manager (ratiopharm) and as Director Key Account Management within the pharmaceutical Industry (Rx, OTC, Gx), as well as with wholesalers and mail-order-pharmacy-companies.
… and many more
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE.
© 2021 Synbiotic SE | All rights reserved
Imprint Privacy policy
